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INTRODUCTION
Over the past two decades we have seen
dramatic improvements in the efﬁcacy,
safety and availibity of antiretroviral
therapy (ART). In the USA and Europe,
life expectancy in people living with HIV
disease approaches that of the
HIV-uninfected.1 Even in regions hardest
hit by the HIV epidemic, effective HIV
therapy has reversed more than a decade
of HIV-related decreased survival.
Despite these advances in ART, motiva-
tions to pursue HIV cure remain strong
due to the toxicity, adherence challenges,
cost and access to care issues associated
with HIV therapy, as well as the persistant
stigma associated with having HIV infec-
tion. Further and renewed motivation
comes from a single case of HIV cure
after stem cell transplantation for acute
leukaemia.
Given the tremendous improvements in
ART, it is important to assess how effect-
ive and safe an HIV cure would need to
be in order to be a viable option com-
pared to ART. We argue that this should
be done prior to the availability of a cure
to provide realistic goals for researchers
and policy makers.
THE VALUE OF MATHEMATICAL AND
COST-EFFECTIVENESS MODELS
One methodology that has been increas-
ingly popular over the past decade is the
use of mathematical simulation modelling
to assess the clinical impact, cost-
effectiveness and clinical role of different
treatment strategies in HIV disease, as
well as in medicine broadly.2 Such models
provide a framework and approach for
using the best available data at any point
in time, and assessing the potential impact
of emerging innovations. Further, unlike
individual trials focused on a single end-
point, these models can integrate multiple
data sources to project beyond the time-
line or outcomes of individual studies and
project long-term outcomes in many
domains, including virologic, immuno-
logic, clinical and cost.3
MODELLING UNCERTAINTY AND
‘WHAT IF’ ANALYSES
Mathematical models have particular
value in their ability to assess uncertainty
in clinical care. Examples include para-
meters determined in clinical trials or
cohort studies (such as the 95% CIs) or
the broader uncertainty over parameters
that have not or cannot readily be mea-
sured in a trial, such as stigma. Another
role of mathematical models is to estimate
changes in care that may arise in the
future; this is clearly of relevance for HIV
cure research. Where many aspects of a
potential intervention are uncertain, as is
the case with the future of cure strategies,
one can use a model to do a ‘what if ’ ana-
lysis. What if a cure had an efﬁcacy of
80% or 95%? What if the severe toxicity
rate was 0.1% or 10%? What if the cost
was $5000 or $50 000 or $500 000? By
varying multiple parameters, individually
or in combination, this type of modelling
can inform the ranges around which new
therapeutic, or diagnostic, approaches
could have a major clinical impact—espe-
cially compared with current therapy.
Importantly, both efﬁcacy and costs can
be estimated.4
UNDERSTANDING VALUE IN HEALTH:
COST ANALYSIS AND
COST-EFFECTIVENESS ANALYSIS
Limited resources for health, in the
context of increasingly effective interven-
tions for multiple acute as well as chronic
diseases, have meant that the demand for
healthcare interventions outstrips the
supply of available resources. This creates
intense pressure to understand the efﬁcacy
of new interventions, as well as the cost
and cost-effectiveness of these strategies.
Cost analysis examines one outcome, cost,
and is used generally for budgeting and
understanding how introducing a new
diagnostic test or therapy will affect
healthcare budgets and costs.
Cost-effectiveness analysis goes further by
attempting to measure ‘value for money’
through an assessment of the costs of an
intervention, as well as the clinical bene-
ﬁts, usually measured in changes in life
expectancy or quality-adjusted life expect-
ancy.5 The outcome of these analyses is
the incremental cost-effectiveness ratio
(ICER), which is denominated in dollars/
year of life saved ($/YLS), dollars/
quality-adjusted life year ($/QALY) saved
or dollars/disability-adjusted life year
($/DALY) saved. The lower the ratio, the
more cost-effective the intervention. This
is effectively a measure of value for
money—how much are we spending to
improve outcomes—compared with other
possible interventions.
DEFINING COST-EFFECTIVENESS
How can one determine if something is
‘cost-effective’? Different countries spend
vastly different resources on health, so
what might be considered cost-effective in
one country might not be in another.
While there is no consensus on what is
‘cost-effective’ in the USA, a widely cited
threshold is that strategies with an ICER
<$100 000/QALY are considered cost-
effective in the USA.6 The WHO historic-
ally has said that cost-effectiveness is
likely related to the annual per person
gross domestic product (GDP) in a
country. An intervention might be consid-
ered ‘cost-effective’ if its ICER were
below three times the per capita GDP; it
might be considered ‘very cost-effective’ if
its ICER were below one times the GDP.7
More recently, it has been suggested that
most resource-limited countries cannot
afford to add to their healthcare portfolio
interventions with ICERs this high, and
that ‘cost-effective’ strategies might be
those with ICERs below half the GDP or
even less.8 Regardless of the exact deﬁn-
ition of what a country might be willing
to pay for healthcare, determining an
ICER allows one to rank the relative value
of different interventions of interest.2
SETTING-SPECIFIC CARE
Current ART, and HIV care more broadly,
differs substantially in different countries.
In the USA, Europe and Australia, guide-
lines for care include ART at the time
infection is diagnosed, with genotype
testing before care and at the time of viro-
logic failure, as well as virologic monitor-
ing and access to over 30 licensed
medications. While the WHO in late 2015
recommended ART at the time of HIV
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diagnosis, based on the results of the
Temprano and START trials, in many
resource-limited settings, criteria for ART
initiation remains at a CD4 threshold of
<350 or <500 cells/μL.3 9 10 Many coun-
tries do not have routine virologic moni-
toring or genotype tests, and integrase
inhibitor-based therapy is not recom-
mended for ﬁrst-line therapy, reserved
only for extraordinary cases or is not avail-
able at all.10 11 Thus, the potential use,
impact, cost and cost-effectiveness of any
cure strategy should be considered in the
context of currently available therapy.
Where therapy is widely available, highly
effective and safe, cure strategies would
offer less incremental value than in settings
where such therapy is not as available.
A ‘WHAT IF’ ANALYSIS OF HIV CURE
IN THE USA
Objective and approach
We set out to use mathematical modelling
to understand what characteristics an HIV
cure strategy would have to have to
improve on currently available ART in the
USA.4 12 For our analysis, we used the
Cost-effectiveness of Preventing AIDS
Complications (CEPAC) model, a vali-
dated and widely published microsimula-
tion of the natural history and treatment
of HIV disease.3 13 14 The model includes
data from multiple cohort studies, clinical
trials and economic analyses and it has
been used to assess a wide variety of treat-
ments, diagnostic tests and testing strat-
egies for HIV disease in the USA as well
as in many other countries. The model
incorporates the most currently available
data and is updated regularly.
Strategies
We incorporated into our analysis three
approaches studied in HIV cure research,
as detailed in Sax et al.4 These include
gene therapy,15 the ‘kick and kill’ strat-
egies, which are similar to chemotherapy
for cancer16 and stem cell transplant.17
We considered a gene therapy strategy as
potentially having lower efﬁcacy but less
toxicity, a chemotherapy strategy having
moderate efﬁcacy and toxicity and a bone
marrow transplant strategy as having the
highest likely efﬁcacy as well as toxicity.
Since none of these strategies are available
currently for HIV cure, in each case, we
varied parameters across a wide range in
sensitivity analyses.
Assumptions going into the model
We used several assumptions meant to
reﬂect the current state of cure research.
First, we assumed that patients eligible for
cure therapy had already been on 1 year
of suppressive ART. Second, if a cure strat-
egy failed, either initially or with later
relapse, we assumed that ART would be
resumed, with no reduction in ART efﬁ-
cacy. Third, we did not include the possi-
bility of reinfection in those cured of HIV.
Fourth, we did not adjust for the impact
of a cure strategy on the likelihood of
individuals developing chronic
‘non-AIDS’ speciﬁc complications, such as
heart disease and cancer. Finally, it is pos-
sible that cure could decrease the poten-
tial of people living with HIV to pass on
HIV, even though we are comparing cure
with ART in those already suppressed.
This omitted factor would make a cure
more attractive relative to ART.
Clinical and cost inputs
Since there are no proven effective cure
strategies, most of the inputs were hypo-
thetical; in terms of toxicity and relapse,
they were based on similar data from
other interventions with gene therapy,
chemotherapy or bone marrow transplant.
We used an initial efﬁcacy of 10%, 20%
and 70% for gene therapy, chemotherapy
and bone marrow transplant, respectively.
Fatal toxicity ranged from 0.1% to 5.0%,
with non-fatal toxicity ranging from 1%
to 55%. Relapse rates after ‘successful’
cure ranged from 0% to 0.5%/month.
Cost inputs were also based, where pos-
sible, on data from similar types of therap-
ies. Cost for gene therapy was $101 000,
for chemotherapy $12 400/month for
24 months, and for bone marrow trans-
plant $123 900, with additional costs of
$1000/month for immunosuppressive
medications. In the model, the cost of ﬁrst-
line ARTwas $24 000/year on average.
Main results of the analysis
We found that, based on the assumptions
in the model, gene therapy would offer a
modest increase in life expectancy com-
pared with ART (from 16.4 to 16.6 dis-
counted QALYs), while it would increase
lifetime costs from $591 000 to $659,000
for an ICER of $331 000/QALY. This is
well above the commonly discussed
willingness-to-pay thresholds in the USA
of ∼$100 000/QALY, suggesting that,
under the assumptions in the model, a
gene therapy approach would not be cost-
effective. For the chemotherapy and bone
marrow transplant approaches, the results
were even less attractive. Because of the
toxicity of both chemotherapy and bone
marrow transplant approaches, particularly
the initial toxicity, they were associated
with the same or worse life expectancy as
continued ART and had substantially
higher costs.
How good would a cure need to be?
By varying parameters in the model indi-
vidually and in combination we could
identify the ‘targets’ at which each of
these strategies might improve life expect-
ancy and be cost-effective compared with
continuing suppressive ART. For gene
therapy, if the efﬁcacy were 22%, the
ICER dropped below $100 000/QALY;
with an efﬁcacy of 34%, it became cost-
saving compared with ART. The efﬁcacy
of chemotherapy had to be 88% to have
an ICER<$100 000/QALY and it never
became cost-saving. Bone marrow trans-
plant had an ICER<$100 000/QALY at an
efﬁcacy of 79%, and became cost-saving
with an efﬁcacy of 80%. For each of these
strategies, if there were no risk of relapse
—that is, the cure was completely durable
—then the efﬁcacy needed to achieve
cost-effectiveness or cost-saving thresholds
was lower. Finally, for all of the strategies,
if an effective cure improved patients’
quality of life compared with their quality
of life on ART, then each of the strategies
became even more attractive. This
depended in large part on the baseline
quality of life for patients receiving ART.
If that quality of life was low (eg, based
on the psychological stressors and stigma
associated with having HIV), then the
potential beneﬁt of cure was higher.
Why cure strategies are unique in HIV
modelling analyses
We and other investigators have examined
multiple HIV interventions, including
HIV testing, ﬁrst-line, second-line and
later ART, as well as diagnostic tests
including viral load and resistance geno-
type testing.13 18–21 For virtually all inter-
ventions in HIV disease—treatments or
diagnostic tests—the intervention
improves survival at added cost, allowing
one to determine whether it has an
attractive cost-effectiveness ratio. It is rare
for a strategy to actually be cost-saving,
including even ‘win–win’ interventions
such as the use of early ART for treatment
as prevention. The primary reason these
are not cost-saving is because each of
these treatment strategies to date involves
continuing therapy lifelong.
Our cure analysis yielded qualitatively
different results. We found that across a
wide range of assumptions, strategies were
unlikely to be cost-effective compared
with ART. In a much narrower range,
there were estimates at which cure might
be cost-effective, that is, increasing life
expectancy as well as cost, with an attract-
ive ICER. But as we continued to assess
each of these parameters, whether efﬁcacy,
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toxicity, relapse rate or cost, the cure strat-
egies then uniformly became cost-saving.
Thus, there is only a narrow parameter
range in which cure would be cost-
effective rather than either cost-saving or
not cost-effective. With high efﬁcacy, cure
could indeed be cost-saving. The primary
explanation for this ﬁnding is that an
effective cure would eliminate the need
for lifelong ART.
Limitations
This type of analysis is most importantly
limited by the lack of real data on cure
strategies. For that reason, we varied each
estimate across a wide range to determine
its impact on the results. Our assumption
that patients undergoing a cure strategy
already be virally suppressed—that is, suc-
cessfully treated—for a year could create a
bias against a cure, since those patients are
likely to continue to do well on ART.
They are, however, the patients thought
most likely to be able to be cured at
present.22 As challenging as HIV eradica-
tion would be in a patient with virologic
suppression, it is currently scientiﬁcally
implausible to imagine doing so in
someone with ongoing high-level viral
replication. We assumed that if a cure
failed, patients could resume ART. If ART
efﬁcacy were reduced, either due to resist-
ance or other reasons, cure would look
worse. If we incorporated the possibility
of reinfection after cure, then cure would
be even less attractive. In terms of
‘non-AIDS’ complications, it is possible
that a cure could decrease these by chan-
ging the factors that are increasing these
complications, or increase them, as has
been seen with chemotherapy for other
diseases. We also do not consider the
potential increased likelihood of transmis-
sion from those on ART, if they have viro-
logic failure, compared with those cured.
Finally, this analysis is based on data from
the USA, including both clinical and cost
data. The results may differ substantially
in other developed as well as resource-
limited settings. Given that the cost of
ART is much lower in resource-limited
settings than in the USA, it is likely, given
increased access to ART via PEPFAR, the
Global Fund and country-speciﬁc pro-
grammes, that a cure strategy would have
to have correspondingly lower cost to be a
viable alternative to effective ART.
CONCLUSIONS
Despite the success of current ART, sub-
stantial resources are being invested in
researching HIV cure strategies. Although
the efﬁcacy, toxicity, relapse and cost para-
meters around HIV cure strategies are not
yet known, it is possible with the use of
mathematical modelling to determine the
set of targets for these parameters under
which HIV cure would be a reasonable
alternative to ART. If novel approaches
can achieve some of these challenging
targets, cure would turn out to be cost-
saving compared with ART, as a lifelong
treatment with ART can then be avoided.
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